Human immunodeficiency virus (HIV) vaccine trials: A novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies

Journal of Virology

Volumn 80, Issue 5, 2006, Pages 2092-2099

  Khurana, Surender ^a   Needham, James ^a   Mathieson, Bonnie ^b   Rodriguez Chavez, Isaac R ^c   Catanzaro, Andrew T ^c   Bailer, Robert T ^c   Kim, Jerome ^d   Polonis, Vicky ^e   Cooper, David A ^f   Guerin, Jan ^f   Peterson, Michael L ^g   Gurwith, Marc ^g   Nguyen, Nga ^a   Graham, Barney S ^c   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d US Army Medical Component Armed Forces Research Institute of Medical Sciences (USAMC AFRIMS)   (Thailand)

^e US Military HIV Research Program   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN P6; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; BACTERIOPHAGE; BLOOD BANK; CLINICAL TRIAL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EPITOPE MAPPING; FALSE POSITIVE RESULT; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SOCIOECONOMICS; VACCINATION;

AIDS VACCINES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FALSE POSITIVE REACTIONS; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; PEPTIDE LIBRARY; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33144470403     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.5.2092-2099.2006     Document Type: Article

References (13)

1. Ackers, M. L., B. Parekh, T. G. Evans, P. Berman, S. Phillips, M. Allen, and J. S. McDougal. 2003. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J. Infect. Dis. 187:879-886.
2. Allen, M., H. Israel, K. Rybczyk, M. A. Pugliese, K. Loughran, L. Wagner, and S. Erb. 2001. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res. Hum. Retrovir. 17:667-674.
3. Belshe, R. B., M. L. Clements, M. C. Keefer, B. S. Graham, L. Corey, R. Sposto, S. Wescott, and D. Lawrence. 1994. Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group. Ann. Intern. Med. 121:584-589.
4. Chuenchitra, T., C. Wasi, S. Louisirirojchanakul, S. Nitayaphan, R. Sutthent, J. H. Cox, M. S. De Souza, A. E. Brown, D. L. Birx, and V. R. Polonis. 2003. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression. AIDS Res. Hum. Retrovir. 19:293-305.
5. Francis, D. P., W. L. Heyward, V. Popovic, P. Orozco-Cronin, K. Orelind, C. Gee, A. Hirsch, T. Ippolito, A. Luck, M. Longhi, V. Gulati, N. Winslow, M. Gurwith, F. Sinangil, and P. W. Berman. 2003. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS 17:147-156.
6. Gilbert, P. B., M. L. Peterson, D. Follmann, M. G. Hudgens, D. P. Francis, M. Gurwith, W. L. Heyward, D. V. Jobes, V. Popovic, S. G. Self, F. Sinangil, D. Burke, and P. W. Berman. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191:666-677.
7. Graham, B. S., and J. R. Mascola. 2005. Lessons from failure-preparing for future HIV-1 vaccine efficacy trials. J. Infect. Dis. 191:647-649.
8. Gross, M., G. R. Seage, K. H. Mayer, R. S. Goldstein, E. Losina, and C. Wold. 1996. Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:406-412.
9. Koblin, B. A., P. Heagerty, A. Sheon, S. Buchbinder, C. Celum, J. M. Douglas, M. Gross, M. Marmor, K. Mayer, D. Metzger, and G. Seage. 1998. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS 12:785-793.
10. Lee, D., B. S. Graham, Y. L. Chiu, P. B. Gilbert, M. J. McElrath, R. B. Belshe, S. P. Buchbinder, H. W. Sheppard, B. A. Koblin, K. H. Mayer, M. C. Keefer, M. J. Mulligan, and C. L. Celum. 2004. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J. Infect. Dis. 190:903-907.
11. Pitisuttithum, P., S. Nitayaphan, P. Thongcharoen, C. Khamboonruang, J. Kim, M. de Souza, T. Chuenchitra, R. P. Garner, D. Thapinta, V. Polonis, S. Ratto-Kim, P. Chanbancherd, J. Chiu, D. L. Birx, A. M. Duliege, J. G. McNeil, and A. E. Brown. 2003. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J. Infect. Dis. 188:219-227.
12. Schwartz, D. H., A. Mazumdar, S. Winston, and S. Harkonen. 1995. Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV type 1 vaccines. Clin. Diagn. Lab. Immunol. 2:268-271.
13. Sheon, A. R., L. Wagner, M. J. McElrath, M. C. Keefer, E. Zimmerman, H. Israel, D. Berger, and P. Fast. 1998. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19:519-526.